Vericel

VCELPhase 3

Vericel is a leader in advanced cell therapies, with a mission to improve the lives of patients with serious conditions through innovative, personalized treatments. The company has achieved significant milestones, including FDA approval for the arthroscopic delivery of its flagship MACI product and the expansion of NexoBrid's label to include pediatric burn patients. Its strategic direction focuses on commercial execution of its approved products, pipeline development, and leveraging its cell therapy manufacturing expertise to capitalize on the rapidly growing regenerative medicine market.

Market Cap

$1.6B

Focus

Cell & Gene Therapy

VCEL · Stock Price

USD 31.414.37 (-12.21%)

Historical price data

AI Company Overview

Technology Platform

Autologous cell therapy platform involving harvesting a patient's own cells (chondrocytes or keratinocytes), expanding and culturing them ex vivo on a scaffold (porcine collagen membrane for MACI), and re-implanting to regenerate functional tissue.

Pipeline Snapshot

15 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Carticel (autologous cultured chondrocyte) implantation	Articular Cartilage	Approved
Ixmyelocel-T	Critical Limb Ischemia	Phase 3
autologous cultured chondrocytes on porcine collagen membrane	Articular Cartilage Defect	Phase 3
Ixmyelocel-T	Osteonecrosis	Phase 3
autologous cultured chondrocytes on porcine collagen membrane	Chondral Defect	Phase 3

Funding History

Total raised: $70M

PIPE$40MUndisclosedDec 15, 2014

IPO$30MUndisclosedJun 26, 1997

Opportunities

Significant growth opportunities exist from the commercial rollout of the newly approved arthroscopic delivery for MACI (MACI Arthro), which can drive higher surgeon adoption, and the expanded pediatric label for NexoBrid.

The overall cell therapy market is projected to grow exponentially, providing a favorable tailwind for Vericel's commercial and platform capabilities.

Risk Factors

Key risks include the commercial challenge of driving adoption of higher-cost, specialized cell therapies against established standards of care, the operational complexity and cost of autologous manufacturing, and ongoing pressure from payers on pricing and reimbursement.

Competition from alternative surgical techniques and emerging technologies also presents a risk.

Competitive Landscape

In cartilage repair, MACI competes with microfracture, osteochondral allograft transplantation, and other cell-based/scaffold technologies. Its autologous nature and new arthroscopic delivery are key differentiators. In burn care, Epicel competes with skin substitutes and autografts, while NexoBrid competes with surgical debridement, offering a selective, non-surgical enzymatic debridement option.

Publications

Patents

Pipeline